Discover 1,431 paid clinical trials in Quebec. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Filter
1
Filter results
Results: 1,431
Active & Responsive
Home-Based tDCS for Depression in BPD
for
Major Depressive Disorder (MDD),
Location: Montreal
Sponsor: Ciusss de L'Est de l'Île de Montréal
Sex: All
Age: 18 - 65
Code: NCT06972368
Recruiting
Active & Responsive
Quebec Low Back Pain Study: Core Dataset
for
Low Back Pain
Location: Montreal
Sponsor: Laval University
Sex: All
Age: 18+
Code: NCT04791891
Recruiting
Active & Responsive
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
for
Diabetic Nephropathies, Kidney Failure, Chronic,
Location: Boston MA, The Bronx NY, Montreal, Syracuse NY, Toronto,
Sponsor: Alessandro Doria
Sex: All
Age: 18 - 70+
Code: NCT06217302
Phase 3, Recruiting
Active & Responsive
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
for
Non-segmental Vitiligo
Location: The Bronx NY, Quebec, Norfolk VA, Rockville MD,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07431177
Phase 2, Recruiting
Active & Responsive
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
for
Obesity, Overweight
Location: East Greenwich RI, Waterbury CT, Chicoutimi,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07684235
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
for
Friedreich Ataxia
Location: Montreal, Philadelphia PA, Toronto, Tampa FL,
Sponsor: Friedreich's Ataxia Research Alliance
Sex: All
Age: 0+
Code: NCT06016946
Recruiting
Active & Responsive
Cannabinoids for Osteoarthritis Pain Effectiveness Trial
for
Osteoarthritis of Knee, Osteoarthritis Hip
Location: Montreal, Toronto
Sponsor: University Health Network, Toronto
Sex: All
Age: 40 - 70+
Code: NCT06878417
Recruiting
Active & Responsive
Exogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome
for
PCOS
Location: Montreal
Sponsor: McGill University
Sex: All
Age: 18 - 40
Code: NCT06155708
Recruiting
Active & Responsive
Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
for
Plaque Psoriasis
Location: Fredericton, Boston MA, Cromwell CT, Quebec,
Sponsor: Oruka Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07449702
Phase 2, Recruiting
Active & Responsive
Brief Skills for Safer Living (Brief-SfSL)
for
Suicide Prevention, Suicide, Suicide and Self-harm, Depression,
Location: St. John's, Grand Falls-Windsor, Corner Brook,
Sponsor: Unity Health Toronto
Sex: All
Age: 18+
Code: NCT06571916
Recruiting
Active & Responsive
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
for
Cardiovascular Disease
Location: Boston MA, East Greenwich RI, Hamden CT, Sherbrooke,
Sponsor: Amgen
Sex: All
Age: 50 - 70+
Code: NCT07136012
Phase 3, Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase 3, Recruiting
Active & Responsive
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
for
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Location: Hillsborough NJ, Montreal, Philadelphia PA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07266831
Phase 2, Phase 3, Recruiting
Active & Responsive
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment